

**Biocon Limited** is an Indian biopharmaceutical company based in Bangalore, India. The Company manufactures generic active pharmaceutical ingredients that are sold in over 120 countries across the globe, including the developed markets of the United States and Europe. It also manufactures novel biologics, as well as, biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets

Biocon Limited was set up in the year 1978 as a joint venture between Biocon Biochemicals Limited of Ireland and an Indian entrepreneur, Kiran Mazumdar-Shaw. Biocon is a fully integrated biopharmaceutical company focused on biopharmaceuticals, customized research and clinical research. The Company has developed a robust drug pipeline and offers active pharmaceutical ingredients, including cardiovascular agents, anti-obesity agents, oral anti-diabetic agents, anti-inflammatory agents and digestive-aid enzymes.

Biocon's presence in the chronic disease segment in India is represented by over 80 brands spread across seven therapeutic segments: Diabetology, Oncotherapeutic, Nephrology, Cardiology, Immunotherapy, Comprehensive Care and Bioproducts.



The Company has strategic alliances with well known pharmaceutical companies including Mylan Inc, Amylin Pharmaceuticals, Inc, DuPont, Bristol-Myers Squibb, Endo Pharmaceuticals, IATRICa Inc, Neopharma, and Vaccinex, Inc. The Company also has commercial and marketing agreements with Pfizer and Ferozsons Laboratories Limited, and licensing agreement with Abraxis BioScience, Inc, as well as strategic collaboration for insulin products with Mylan, Inc.

The Company's brands include Herceptin, Enbrel, MabThera, Remicade, Lantus, Humalog and NovoLog.

## SWOT analysis of Biocon Limited

### **SWOT - Strengths**

- skilled workforce
- barriers of market entry
- existing distribution and sales networks
- high profitability and revenue
- monetary assistance provided

### **SWOT - Weaknesses**

- high investments in research and development
- high loan rates are possible

### **SWOT - Opportunities**

- growth rates and profitability
- global markets
- income level is at a constant increase
- growing demand
- growing economy
- new acquisitions
- new markets

### **SWOT - Threats**

- increasing costs
- government regulations

Biocon's average interest coverage ratio over the last 5 financial years has been 122.48 times which indicates that the Company has been generating enough for the shareholders after servicing its debt obligations.

## Current situation of Biocon.

NEW DELHI: Biotechnology major Biocon, today said it has launched its cancer biosimilar drug KRABEVA in India.

The biosimilar product will be used for the treatment of patients with metastatic colorectal cancer and other types of lung, kidney, cervical, ovarian and brain cancers in India, Biocon said in a filing to the BSE.

Biocon CEO and Joint MD Arun Chandavarkar said: "With KRABEVA, we intend to provide a high quality, world-class biosimilar Bevacizumab as an affordable therapy option for patients of various types of cancer."

The company believes that the product will be an important addition to its oncology portfolio of novel biologics as well as biosimilars, which are making a significant impact in the realm of cancer care in India, he added.

KRABEVA is the second key oncologic biosimilar product from Biocon's global biosimilar portfolio to be launched in India to address the unmet patient need for affordable, biological therapies, the company said.

"It is being offered to patients at an MRP of Rs 24,000 for 100 mg/4 ml vials and Rs 39,990 for 400 mg/16 ml vials..." it added.

[\(information from ECONOMIC TIMES\)](#)

The Delhi High Court has allowed pharmaceutical firms Biocon Ltd and Mylan Pharmaceuticals Pvt Ltd to continue manufacturing and marketing their breast cancer drug under brand names CANMAB and HERTRAZ.

Justice Manmohan Singh made it clear that these companies would not call their product "bio similar" to 'Herceptin, Herclon, Biceltis', the brand names of products by firm Roche Products (India) Pvt Ltd.

Biocon said its product portfolio will not be affected by the court order preventing the drug maker from calling its breast cancer medicine Trastuzumab a bio-similar of Roche's Herceptin.

"The High Court judgement does not restrict the sale and manufacture of Biocon's Trastuzumab, which is in the interest of patients...the current judgement will not affect our product portfolio," a Biocon spokesperson said in an emailed statement.

The Biocon spokesperson said: "We understand it has some observations with respect to packaging and labeling, which we will address appropriately. Our Trastuzumab, CANMAb has undergone all applicable comparability studies."

When contacted, a Roche spokesperson said the "ruling sends a strong, positive signal that the development, manufacture and approval of biosimilars in India must be subject to rigorous clinical and regulatory standards as per the applicable law".

"The court has made clear that the approvals granted to these companies are not in accordance with the existing protocol for biosimilars and, therefore, their drugs cannot be considered biosimilars," the spokesperson added.

The court, while passing the order on a petition filed by Swiss pharmaceutical firm Roche against Biocon and Mylan, said that a bio similar, a medical product almost identical to an original product manufactured by a different firm, would need to follow stringent guidelines framed in 2012 for getting regulatory approvals.

The court allowed the sale and manufacture of affordable cancer drugs by Biocon and Mylan with certain restrictions on packaging and labelling and regulatory process.

[\(Information gathered form TIMES OF INDIA\)](#)

I think if Biocon will continue it's continued momentum then no any other company will defeat it because The Company has maintained an average dividend yield of **0.82 %** over the last 5 financial years.